457 related articles for article (PubMed ID: 22673023)
21. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA
Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071
[TBL] [Abstract][Full Text] [Related]
22. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
[TBL] [Abstract][Full Text] [Related]
23. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
Blair JE; Zannad F; Konstam MA; Cook T; Traver B; Burnett JC; Grinfeld L; Krasa H; Maggioni AP; Orlandi C; Swedberg K; Udelson JE; Zimmer C; Gheorghiade M;
J Am Coll Cardiol; 2008 Nov; 52(20):1640-8. PubMed ID: 18992654
[TBL] [Abstract][Full Text] [Related]
24. Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial.
Payvar S; Spertus JA; Miller AB; Casscells SW; Pang PS; Zannad F; Swedberg K; Maggioni AP; Reid KJ; Gheorghiade M;
Eur J Heart Fail; 2013 Dec; 15(12):1382-9. PubMed ID: 23858000
[TBL] [Abstract][Full Text] [Related]
25. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial.
Rossi J; Bayram M; Udelson JE; Lloyd-Jones D; Adams KF; Oconnor CM; Stough WG; Ouyang J; Shin DD; Orlandi C; Gheorghiade M
Acute Card Care; 2007; 9(2):82-6. PubMed ID: 17573581
[TBL] [Abstract][Full Text] [Related]
26. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.
Kimura K; Momose T; Hasegawa T; Morita T; Misawa T; Motoki H; Izawa A; Ikeda U
J Cardiol; 2016 May; 67(5):399-405. PubMed ID: 26692119
[TBL] [Abstract][Full Text] [Related]
27. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure.
Goldsmith SR; Gilbertson DT; Mackedanz SA; Swan SK
J Card Fail; 2011 Dec; 17(12):982-9. PubMed ID: 22123359
[TBL] [Abstract][Full Text] [Related]
28. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y
Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
[TBL] [Abstract][Full Text] [Related]
29. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial.
Giamouzis G; Butler J; Starling RC; Karayannis G; Nastas J; Parisis C; Rovithis D; Economou D; Savvatis K; Kirlidis T; Tsaknakis T; Skoularigis J; Westermann D; Tschöpe C; Triposkiadis F
J Card Fail; 2010 Dec; 16(12):922-30. PubMed ID: 21111980
[TBL] [Abstract][Full Text] [Related]
30. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials.
Pang PS; Gheorghiade M; Dihu J; Swedberg K; Khan S; Maggioni AP; Grinfeld L; Zannad F; Burnett JC; Ouyang J; Udelson JE; Konstam MA
Am Heart J; 2011 Jun; 161(6):1067-72. PubMed ID: 21641352
[TBL] [Abstract][Full Text] [Related]
31. Hyponatremia, heart failure, and the role of tolvaptan.
O'Connell JB; Alemayehu A
Postgrad Med; 2012 Mar; 124(2):29-39. PubMed ID: 22437213
[TBL] [Abstract][Full Text] [Related]
32. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study.
Matsue Y; Suzuki M; Nagahori W; Yoshida K; Onishi Y; Satoh Y; Ono Y; Nishioka T; Noda M; Sugi K; Torii S; Tejima T; Sakurada H; Yamaguchi S; Okishige K; Fujii H; Takahashi A
Cardiovasc Drugs Ther; 2014 Feb; 28(1):73-7. PubMed ID: 24048511
[TBL] [Abstract][Full Text] [Related]
33. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954
[TBL] [Abstract][Full Text] [Related]
34. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC;
J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154
[TBL] [Abstract][Full Text] [Related]
35. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction.
Matsue Y; Ter Maaten JM; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; van der Meer P; Damman K; Voors AA; Goldsmith SR
Clin Res Cardiol; 2017 Oct; 106(10):802-812. PubMed ID: 28540483
[TBL] [Abstract][Full Text] [Related]
36. Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure.
Suzuki S; Yoshihisa A; Yamaki T; Sugimoto K; Kunii H; Nakazato K; Abe Y; Saito T; Ohwada T; Suzuki H; Saitoh S; Kubota I; Takeishi Y;
Int Heart J; 2015; 56(2):213-8. PubMed ID: 25740399
[TBL] [Abstract][Full Text] [Related]
37. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
[TBL] [Abstract][Full Text] [Related]
38. Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload.
Konstam MA; Kiernan M; Chandler A; Dhingra R; Mody FV; Eisen H; Haught WH; Wagoner L; Gupta D; Patten R; Gordon P; Korr K; Fileccia R; Pressler SJ; Gregory D; Wedge P; Dowling D; Romeling M; Konstam JM; Massaro JM; Udelson JE;
J Am Coll Cardiol; 2017 Mar; 69(11):1409-1419. PubMed ID: 28302292
[TBL] [Abstract][Full Text] [Related]
39. Clinical experience with low-dose continuous infusion of furosemide in acute heart failure: assessment of efficacy and safety.
Ng TM; Hshieh S; Chan CY; Elkayam U
J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):373-81. PubMed ID: 22610091
[TBL] [Abstract][Full Text] [Related]
40. Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis.
Mori T; Oba I; Koizumi K; Kodama M; Shimanuki M; Tanno M; Chida M; Saito M; Kiyomoto H; Miyazaki M; Ogawa S; Sato H; Ito S
Adv Perit Dial; 2013; 29():33-7. PubMed ID: 24344488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
